

Katherine Stemke Stemke-Hale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2984637/publications.pdf>

Version: 2024-02-01

38
papers

10,289
citations

159585

30
h-index

302126

39
g-index

39
all docs

39
docs citations

39
times ranked

16472
citing authors

#	ARTICLE	IF	CITATIONS
1	A Landscape of Driver Mutations in Melanoma. <i>Cell</i> , 2012, 150, 251-263.	28.9	2,247
2	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. <i>Cancer Cell</i> , 2007, 12, 395-402.	16.8	1,471
3	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 6084-6091.	0.9	916
4	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. <i>Cancer Research</i> , 2009, 69, 4116-4124.	0.9	768
5	Incidence and Outcome of <i>BRCA</i> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1082-1089.	7.0	487
6	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. <i>Cancer Cell</i> , 2009, 16, 21-32.	16.8	472
7	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. <i>Nature Genetics</i> , 2011, 43, 442-446.	21.4	449
8	High Frequency of <i>PIK3R1</i> and <i>PIK3R2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. <i>Cancer Discovery</i> , 2011, 1, 170-185.	9.4	419
9	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 7538-7546.	7.0	221
10	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	30.7	219
11	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. <i>Genome Research</i> , 2012, 22, 2120-2129.	5.5	206
12	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1093-1101.	4.1	204
13	Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. <i>Biomicrofluidics</i> , 2013, 7, 11807.	2.4	186
14	Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2472-2478.	7.0	185
15	Activity of dasatinib against <i>L576P KIT</i> mutant melanoma: Molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2079-2085.	4.1	178
16	Direct Association between the Yeast Rad51 and Rad54 Recombination Proteins. <i>Journal of Biological Chemistry</i> , 1996, 271, 33181-33186.	3.4	153
17	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. <i>Cancer Research</i> , 2014, 74, 4845-4852.	0.9	148
18	Correlations between the dielectric properties and exterior morphology of cells revealed by dielectrophoretic field-flow fractionation. <i>Electrophoresis</i> , 2013, 34, 1042-1050.	2.4	143

#	ARTICLE	IF	CITATIONS
19	Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. <i>Nature Genetics</i> , 2011, 43, 1119-1126.	21.4	133
20	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. <i>Cancer Cell</i> , 2010, 18, 423-435.	16.8	129
21	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3654-3662.	7.0	121
22	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72.	2.4	111
23	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 333-343.	2.5	106
24	Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems. <i>Biomicrofluidics</i> , 2013, 7, 11808.	2.4	101
25	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 47-53.	1.4	74
26	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	4.1	72
27	A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. <i>BMC Cancer</i> , 2014, 14, 120.	2.6	68
28	Dynamic physical properties of dissociated tumor cells revealed by dielectrophoretic field-flow fractionation. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 850.	1.3	58
29	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. <i>PLoS ONE</i> , 2013, 8, e65144.	2.5	50
30	A Library-Selected, Langerhans Cell-Targeting Peptide Enhances an Immune Response. <i>DNA and Cell Biology</i> , 2004, 23, 742-752.	1.9	34
31	Screening the whole genome of a pathogen in vivo for individual protective antigens. <i>Vaccine</i> , 2005, 23, 3016-3025.	3.8	32
32	Systematic analysis of genotype-specific drug responses in cancer. <i>International Journal of Cancer</i> , 2012, 131, 2456-2464.	5.1	28
33	<i>ZNF668</i> Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6524-6534.	0.9	26
34	Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy. <i>Cancer Science</i> , 2012, 103, 400-407.	3.9	18
35	Expression Library Immunization: a Road Map for Discovery of Vaccines against Infectious Diseases. <i>Infection and Immunity</i> , 2005, 73, 7089-7098.	2.2	16
36	Detection algorithm for the validation of human cell lines. <i>International Journal of Cancer</i> , 2012, 131, E1024-30.	5.1	13

#	ARTICLE	IF	CITATIONS
37	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. <i>Modern Pathology</i> , 2013, 26, 544-552.	5.5	13
38	Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein. <i>Current Oncology Reports</i> , 2006, 8, 484-491.	4.0	10